Quest Diagnostics Inc
DGX: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|y^ | LOCK|@#zQ@ | LOCK|Tp!T^q@ |
Quest Diagnostics: Strong Organic Gains Seen in Quarter, but PAMA Cuts Loom on Horizon
Quest delivered third-quarter results that included revenue and earnings growth of 10% and 26%, respectively. Management indicated it estimates potential PAMA cuts in 2027 could amount to 1% of total revenue.
